Læknablaðið - 15.09.2009, Page 42

nvD u 11 ri
O J I Jli\ Jn
Nýjar og einfaldari pakkningastærðir
4 vikna
upphafspakki
CHAMP/X 0,5mg
cm/'M/’/x
UgeA/ika/Uke 1
J)
Uge/Vika/Uke 2
J)
VarenicliH
FILMOVERTBOKNETAB^ Varenidin
SS£5S“*
© ©8
■'ye/vika/Uke 4
* J
5startl>altniS^jíS*r
íi j- ir j*
- K,^r
íS 0« !i, •
12 1 ^ - . *
I®

i
Heimildir:
1. Gonzales D et al. Varenicline, an á4á2 nicotinic acethylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking
cessation. A randomized controlled trial. JAMA 2006; 296(1 ):47-55
2. Jorenby DE et al. Efficacy of varenicline, an á4á2 nicotinic acethylcholine receptor partial agonist, vs sustained-release bupropion and placebo for
smoking cessation. A randomized controlled trial. JAMA 2006; 296(1 ):56-63
3. Tonstad S et al. Effect of maintenance therapy with varenicline on smoking cessation. A randomized controlled trial. JAMA 2006; 296(1 ):64-71
4. Aubin H et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax online,
February 8th 2008. Downloaded from thorax.bmj.com on 19. February 2008.
*Byggt á MNWS (Minnesota Nicotine Withdrawal Scale), stuttur spurningalisti um löngun í að reykja og aðlagaður spurningalisti um reykingar.